BHV1400-102 is an ongoing multi-center, 1-year, open-label study evaluating BHV-1400 as a potential treatment for IgA Nephropathy. BHV-1400 was designed to selectively target and remove disease-causing Gd IgA1 without removing normal immunoglobulins.
All study participants will receive the study drug; there is no placebo arm. The purpose of the study is to assess the safety and tolerability of BHV-1400 in people with immunoglobulin A nephropathy (IgAN) , to track the reduction of Gd-IgA1 and how this reduction impacts the measures of proteinuria and kidney function. In addition, the level of healthy antibodies (IgA, IgE, IgG and IgM) are monitored. All study-related tests will be provided to participants during their study participation, free of charge.
Learn More
